Related Experiment Video

Updated: May 6, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.1K

Protein kinase C: an attractive target for cancer therapy

Barbara Marengo1, Chiara De Ciucis, Roberta Ricciarelli

  • 1G. Gaslini Institute, L.go G. Gaslini 5, 16147, Genoa, Italy. cinzia.domenicotti@unige.it.

Cancers
|November 12, 2013
PubMed

Insights

Understanding how protein kinase C (PKC) regulates apoptosis and chemoresistance is key. This knowledge could lead to new cancer therapies that reduce drug dosages and prevent treatment resistance.

Area of Science:

  • Cancer Biology
  • Molecular Oncology
  • Cell Signaling

Background:

  • Apoptosis is crucial in cancer development and chemoresistance.
  • Defects in apoptotic pathways contribute to tumor cell chemoresistance.
  • Protein kinase C (PKC) is implicated in cancer progression and therapy resistance.

Purpose of the Study:

  • To elucidate the role of Protein Kinase C (PKC) in regulating apoptosis.
  • To understand how PKC influences the development of chemoresistance in tumor cells.
  • To explore the potential of PKC as a therapeutic target for overcoming cancer drug resistance.

Main Methods:

  • Review of pre-clinical and clinical data on Protein Kinase C (PKC) in cancer.
  • Analysis of intracellular signaling pathways central to apoptosis.
  • Investigation of mechanisms linking PKC to chemoresistance.

Main Results:

  • Pre-clinical and clinical evidence suggests Protein Kinase C (PKC) is a viable target for cancer therapy.
  • Dysregulation of apoptotic pathways involving PKC is linked to chemoresistance.
  • Targeting PKC may offer a strategy to enhance chemotherapy effectiveness.

Conclusions:

  • A comprehensive understanding of PKC's role in apoptosis and chemoresistance is essential.
  • Developing PKC-based therapies could reduce chemotherapy dosages.
  • Targeting PKC may prevent the emergence of drug-resistant tumors.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.3K
Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

18.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K